Recent News

• 11.20.2025 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 11.06.2025 - Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
• 11.03.2025 - Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.22.2025 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 10.09.2025 - Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
• 10.07.2025 - Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

Recent Filings

• 11.05.2025 - 144 Report of proposed sale of securities
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.04.2025 - 144 Report of proposed sale of securities
• 11.03.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 11.03.2025 - 8-K Current report
• 11.03.2025 - 144 Report of proposed sale of securities
• 11.03.2025 - EX-99.1 EX-99.1
• 10.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.08.2025 - 144 Report of proposed sale of securities